Yannick Schuurmans

Health

Kela’s Reimbursement Policy Shift Sparks Debate Over Legal Compliance, Patient Safety, and Healthcare Equality – Coalition Party Ministers Propose Centralization as Opposition and Government Trade Blame, While Patients Express Confusion and Fear

From the beginning of July, Kela has discontinued the reimbursement of certain high-cost medications, including cancer treatments, when administered in public healthcare. The change shifts an estimated €100 million in medication costs to wellbeing services counties, which are already facing financial strain. Ilta-Sanomat reports that the policy may

lock-1